image
Healthcare - Biotechnology - NASDAQ - US
$ 4.25
7.71 %
$ 38.2 M
Market Cap
-1.07
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 7, 2025.

The intrinsic value of one CLNN stock under the worst case scenario is HIDDEN Compared to the current market price of 4.25 USD, Clene Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 7, 2025.

The intrinsic value of one CLNN stock under the base case scenario is HIDDEN Compared to the current market price of 4.25 USD, Clene Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 7, 2025.

The intrinsic value of one CLNN stock under the best case scenario is HIDDEN Compared to the current market price of 4.25 USD, Clene Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CLNN

image
$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
342 K REVENUE
-47.71%
-33.1 M OPERATING INCOME
18.37%
-39.4 M NET INCOME
20.41%
-21.3 M OPERATING CASH FLOW
29.32%
6.32 M INVESTING CASH FLOW
521.35%
-1.53 M FINANCING CASH FLOW
-3.63%
81 K REVENUE
-10.99%
-4.08 M OPERATING INCOME
52.91%
-751 K NET INCOME
94.46%
-5.01 M OPERATING CASH FLOW
-3.00%
0 INVESTING CASH FLOW
100.00%
2.67 M FINANCING CASH FLOW
5.74%
Balance Sheet Clene Inc.
image
Current Assets 16.2 M
Cash & Short-Term Investments 12.2 M
Receivables 391 K
Other Current Assets 3.61 M
Non-Current Assets 11.2 M
Long-Term Investments 0
PP&E 11.1 M
Other Non-Current Assets 58 K
44.46 %13.21 %40.68 %Total Assets$27.3m
Current Liabilities 10.3 M
Accounts Payable 1.24 M
Short-Term Debt 1.28 M
Other Current Liabilities 7.77 M
Non-Current Liabilities 25.9 M
Long-Term Debt 19.6 M
Other Non-Current Liabilities 6.34 M
3.43 %3.55 %21.46 %54.04 %17.53 %Total Liabilities$36.2m
EFFICIENCY
Earnings Waterfall Clene Inc.
image
Revenue 342 K
Cost Of Revenue 70 K
Gross Profit 272 K
Operating Expenses 33.4 M
Operating Income -33.1 M
Other Expenses 6.31 M
Net Income -39.4 M
5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)342k(70k)272k(33m)(33m)(6m)(39m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
79.53% GROSS MARGIN
79.53%
-9676.32% OPERATING MARGIN
-9676.32%
-11520.47% NET MARGIN
-11520.47%
444.85% ROE
444.85%
-144.13% ROA
-144.13%
-180.53% ROIC
-180.53%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Clene Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)20192019202020202021202120222022202320232024202420252025
Net Income -39.4 M
Depreciation & Amortization 1.64 M
Capital Expenditures -15 K
Stock-Based Compensation 7.95 M
Change in Working Capital 3.21 M
Others 8.69 M
Free Cash Flow -21.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Clene Inc.
image
CLNN has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Clene Inc.
image
Sold
0-3 MONTHS
21.4 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
583 K USD 3
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates Clene Inc. (CLNN) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to loss of $1.80 per share a year ago. zacks.com - 1 month ago
Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights Clene preparing for upcoming meeting in the second quarter with the U.S. Food and Drug Administration (FDA) to reach agreement on its statistical analysis plan (SAP) regarding analysis of neurofilament light chain (NfL) biomarker data Clene collecting NfL biomarker data from its large National Institute of Health (NIH)-sponsored Expanded Access Protocol (EAP), for evaluation in the third quarter to satisfy the FDA recommendation for additional NfL data Clene reported new data supporting the remyelination and neuronal repair associated with CNM-Au8 ® treatment in a late-breaking science session at the American Academy of Neurology (AAN) 2025 Annual Meeting Clene released new data from a cross-regimen analysis of HEALEY ALS Platform Trial, showing that CNM-Au8 significantly extends survival in patients with ALS Clene planning to submit a New Drug Application (NDA) in the fourth quarter of 2025 for potential Accelerated Approval of CNM-Au8 in ALS Cash and cash equivalents of $9.8 million as of March 31, 2025, providing cash runway into the third quarter of 2025 SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its first quarter 2025 financial results and provided recent updates on its CNM-Au8 programs. “Prolonging survival for people living with ALS is the critical mission for Clene. globenewswire.com - 1 month ago
Clene to Present at the Emerging Growth Conference SALT LAKE CITY, April 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to advancing therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. globenewswire.com - 2 months ago
Clene to Present at the Jones Healthcare and Technology Innovation Conference SALT LAKE CITY, April 01, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Jones Healthcare and Technology Innovation Conference and host 1x1 investor meetings. globenewswire.com - 2 months ago
Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates Clene Inc. (CLNN) came out with a quarterly loss of $1.67 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to loss of $1.20 per share a year ago. zacks.com - 2 months ago
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights SALT LAKE CITY, March 24, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its full year 2024 financial results and provided recent operating highlights for the clinical programs in ALS and MS. globenewswire.com - 2 months ago
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival Advantage New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival Advantage globenewswire.com - 3 months ago
Clene to Present at the 37TH Annual Roth Conference SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a fireside chat at the 37th Annual Roth Conference and host 1x1 investor meetings. globenewswire.com - 3 months ago
Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11 NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Rob Etherington, CEO, and Morgan Brown, CFO, of Clene Inc., will be presenting at this year's Investor Summit Virtual on March 11th. About Clene Inc. Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. accessnewswire.com - 3 months ago
Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkers APST Research data includes thousands of people living with ALS including clinical, survival, and longitudinal NfL data Clene plans to analyze the APST ALS NfL biomarker and clinical dataset to compare NfL change from its ongoing NIH-sponsored EAP to address the FDA's request for supportive evidence of CNM-Au8's effect on NfL reduction observed in the HEALEY ALS Platform Trial Clene plans to submit a New Drug Application (NDA) in second-half 2025 SALT LAKE CITY, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it has entered into an agreement with German-based APST Research GmbH (APST) to utilize its extensive NfL database to support the FDA-recommended analyses of CNM-Au8 ® 's effect on NfL decline in participants in ongoing Expanded Access Protocols (EAPs). APST maintains one of the largest comprehensive ALS repositories of people living with ALS, including demographic data, clinical data, ALS motor phenotypes and biomarker data, specifically, serum neurofilament light chain (sNfL). globenewswire.com - 3 months ago
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it recently received written guidance from the Division of Neurology 1 (DN1), of the U.S. Food and Drug Administration (FDA) regarding a potential accelerated approval pathway for CNM-Au8 ® in ALS. globenewswire.com - 6 months ago
Clene Inc. (CLNN) Reports Q3 Loss, Misses Revenue Estimates Clene Inc. (CLNN) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $1.34. This compares to loss of $0.40 per share a year ago. zacks.com - 7 months ago
8. Profile Summary

Clene Inc. CLNN

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 38.2 M
Dividend Yield 0.00%
Description Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Contact 6550 South Millrock Drive, Salt Lake City, UT, 84121 https://clene.com
IPO Date Oct. 18, 2018
Employees 75
Officers Dr. Benjamin M. Greenberg M.D., M.H.S. Head of Medical Mr. Jerry Miraglia J.D. General Counsel & Corporate Secretary Mr. Morgan R. Brown CPA, M.B.A. Chief Financial Officer Ms. Mary Anne Mcneil Head of Human Resources Mr. Michael T. Hotchkin Chief Development Officer Mr. Mark G. Mortenson ESQ. Chief Science Officer Mr. Robert Etherington MBA Chief Executive Officer, President & Director